Dr. Kevin B. Kim is a medical oncologist. He currently serves as the Medical Director of the Melanoma Clinical Research Program at California Pacific Medical Center (CPMC) in San Francisco, CA. He graduated from the University of Illinois at Chicago, College of Medicine, and completed his internal medicine residency at the Mayo Clinic, Rochester, MN and did a fellowship in hematology/oncology at The University of Texas MD Anderson Cancer Center, Houston, TX. He joined the department of Melanoma Medical Oncology at MD Anderson Cancer Center in 2001. He was an Associate Professor there until his recent move to CPMC. Dr. Kim is a recognized expert in the field of melanoma, and his research has focused on targeted therapy and immunotherapy. His research has helped early clinical development of BRAF inhibitors, such as vemurafenib, dabrafenib, MEK inhibitors, and trametinib, which are now standard of care for patients with BRAF mutated melanoma. His research has also included the clinical investigation of therapy for other mutations, including cKIT and NRAS and also antiangiogenic drugs as well as novel immunotherapy, such as ipilimumab, anti-PD1 antibodies and cancer vaccines. He is also a senior editor for the journal Melanoma Management.
University of Illinois at Chicago, College of Medicine, Chicago, IL, 1995
Internal Medicine, Mayo Clinic, Rochester, MN, 1998
Medical Oncology/Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001
American Board of Medical Oncology, 2001 - Current
University of California at Berkeley, CA, BA in Biochemistry, 1990
Fellowship Research Grant Award, The University of Texas, M.D. Anderson Cancer Center, 1998